Neuro-Zone has entered into a commercial agreement through which it will leverage its sales network to support BiomimX‘s business development by identifying and introducing potential clients, as well as conducting marketing activities.
In addition, Neuro-Zone will perform these activities specifically for the service line related to the uKnee model, focusing on applications for rheumatoid arthritis and osteoarthritis.
Lastly, the agreement will allow Neuro-Zone to enhance its technological offering in the field of preclinical models for studying inflammatory musculoskeletal disorders. By adding uKnee, BiomimX’s proprietary model, to its portfolio, Neuro-Zone will provide a new technological solution aimed at reducing the risks associated with the development of new drugs and medical devices for osteoarthritis.
BiomimX
BiomimX is an innovative startup, incubated at Bio4Dreams, that has developed technology capable of recreating functional human mini-organs in vitro to test the efficacy and toxicity of new drugs during the preclinical phase. The technology, called uBeat™, enables the application of controlled mechanical stimulation to 3D cellular constructs cultivated within miniaturized platforms (beating organs-on-chip).
Among the currently available applications of the platform are uHeart, a model of a beating human heart, and uKnee, a model of a human joint affected by osteoarthritis.
